<DOC>
	<DOC>NCT02473393</DOC>
	<brief_summary>To assess safety, efficacy and pharmacokinetics of multiple dosesin patients with Bacterial Enteritis caused by Clostridium difficile infection(CDI) or Enteric infection.</brief_summary>
	<brief_title>A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis</brief_title>
	<detailed_description />
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>The patient provides written, informed consent before the clinical trial is initiated The patient has distinctive symptoms and findings of bacterial enteritis The patient has bacterial enteritis with one or more of the following causative pathogens either proven or presumed: C. difficile, Salmonella, Campylobacter, pathogenic E. coli, and other bacteria estimated to cause bacterial enteritis The patient and his/her partner are willing to take contraceptive measures from initiation of investigational medicinal products (IMPs) to 4 weeks after administration of IMPs The patient has severe or progressive underlying disease or complication, making it difficult to ensure safety in the study or proper efficacy assessment The patient has a current diagnosis or history of convulsive disorders, such as convulsion and epilepsy The patient has a severe hepatic dysfunction The patient has a severe cardiac dysfunction The patient has cardiac arrhythmia or congenital or sporadic long QTc syndrome. Or the patient is treated with a drug reported to prolong QTc interval The patient has a moderate or severe renal dysfunction Women with confirmed or suspected pregnancy or breastfeeding women Patients judged to be ineligible by the investigator for any other reasons</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>